---
title: "Arrowhead Pharmaceuticals, Inc. (ARWR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ARWR.US.md"
symbol: "ARWR.US"
name: "Arrowhead Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T16:10:30.421Z"
locales:
  - [en](https://longbridge.com/en/quote/ARWR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARWR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARWR.US.md)
---

# Arrowhead Pharmaceuticals, Inc. (ARWR.US)

## Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [arrowheadpharma.com](https://arrowheadpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: D (0.61)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 203 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 14.09% |  |
| Net Profit YoY | -109.01% |  |
| P/B Ratio | 16.97 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10416376702.95 |  |
| Revenue | 622009000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -46.39% | E |
| Profit Margin | -48.38% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 14.09% | B |
| Net Profit YoY | -109.01% | E |
| Total Assets YoY | 44.15% | A |
| Net Assets YoY | -12.47% | E |
| Cash Flow Margin | 12.07% | D |
| OCF YoY | 14.09% | B |
| Turnover | 0.32 | D |
| Gearing Ratio | 73.60% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Arrowhead Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "14.09%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-109.01%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "16.97",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10416376702.95",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "622009000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-46.39%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-48.38%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "14.09%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-109.01%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "44.15%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-12.47%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "12.07%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "14.09%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "73.60%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -34.62 | 528/386 | 48.55 | 44.08 | 41.41 |
| PB | 16.97 | 412/386 | 18.21 | 10.92 | 3.70 |
| PS (TTM) | 16.75 | 189/386 | 10.46 | 8.17 | 4.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 50% |
| Overweight | 4 | 29% |
| Hold | 2 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 72.85 |
| Highest Target | 110.00 |
| Lowest Target | 35.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ARWR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ARWR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ARWR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ARWR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**